Concepedia

Author

Xianxian Zheng

Pfizer (United States)

Also Known As

Konstantinos Tsaparikos, X Zheng, X. Zheng, X.N. Zheng, Xian-xian Zheng, XianXian Zheng, Xianxian Zheng, xianxian zheng

42

Publications

4.5K

Citations

24

H-Index

67

Concepts

All Affiliations

Pfizer (United States)Dana-Farber Cancer InstituteSichuan UniversityThe University of Texas MD Anderson Cancer CenterEmory University
XZ

About

Xianxian Zheng is an author at Pfizer (United States) specializing in medicine, pathology, and pharmacology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

10

10

1.7K

2

Natural Sciences

2

2

36

3

Engineering

1

1

96

4

Health Sciences

1

1

45

5

Public Health

1

1

188

Xianxian Zheng

×

24

Publications

4K

Citations

22

H-Index

YearCitations

Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts

David W. Fry, Patricia J. Harvey, Paul R. Keller,

Molecular Cancer Therapeutics

2004

1.2K

Familial mitochondrial encephalomyopathy (MERRF): Genetic, pathophysiological, and biochemical characterization of a mitochondrial DNA disease

Douglas C. Wallace, Xianxian Zheng, Marie T. Lott,

Cell

1988

571

Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene.

Daniel T. Eitzman, Ronald D. McCoy, Xianxian Zheng,

Journal of Clinical Investigation

1996

558

A Phase I, Dose-Finding Study in Patients with Advanced Solid Malignancies of the Oral γ-Secretase Inhibitor PF-03084014

Wells A. Messersmith, Geoffrey I. Shapiro, James M. Cleary,

Clinical Cancer Research

2014

214

Vitronectin is not essential for normal mammalian development and fertility.

Xianxian Zheng, Thomas L. Saunders, Sally A. Camper,

Proceedings of the National Academy of Sciences

1995

188

PEST Domain Mutations in Notch Receptors Comprise an Oncogenic Driver Segment in Triple-Negative Breast Cancer Sensitive to a γ-Secretase Inhibitor

Kai Wang, Qin Zhang, Danan Li,

Clinical Cancer Research

2015

146

Comparative Effects of Thiazolidinediones on in Vitro P450 Enzyme Induction and Inhibition

Jasminder Sahi, Christopher B. Black, Geraldine A. Hamilton,

Drug Metabolism and Disposition

2003

111

Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study

Giovanni Martinelli, Vivian G. Oehler, Cristina Papayannidis,

The Lancet Haematology

2015

109

Vitronectin Inhibits the Thrombotic Response to Arterial Injury in Mice

William P. Fay, Andrew C. Parker, Maria Ansari,

Blood

1999

108

An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735

Kenneth E. Hook, Scott J. Garza, Maruja E. Lira,

Molecular Cancer Therapeutics

2012

96

Page 1